

Gilles EDAN, MD, Prof
PUPH Exceptional Level,
CURRICULUM VITAE

ON-GOING POSITION

Head of the Neurosciences Departement
@ the University Hospital of Rennes
Head of the Neurosciences Research Team « CIC-P INSERM 14 14 »

PONTCHAILLOU HOSPITAL

Neurology

Rue Henri le Guilloux 35033 RENNES CEDEX 9

E-mail : gilles.edan@chu-rennes.fr

Tel : +33 (0)2 99 28 41 22 ; Fax : +33 (0)2 99 28 41 32

Birth date: 02/06/1952

Web of Science



Search

Search Results

My Tools

Search History

Marked List

Citation report for 468 results from All Databases between 1950 and 2018 Go

You searched for: AUTHOR: (Edan G) ...More

Timespan: All years.

...Less

This report reflects citations to source items indexed within All Databases.

Export Data: Save to Excel File

Total Publications

468



h-index

51

Average citations per item

44,92

Sum of Times Cited

21 022

Without self citations

20 689


Citing articles

13 769

Without self citations

13 639

Sum of Times Cited per Year



TRAINING

3RD CYCLE

- Internal Medecin - 1984 (Rennes)
- Nutrition endocrinology -1983 (Nantes)
- Medical Doctor (First class honours) 1981 (Rennes)
- Neurology – 1981 (Rennes)
- Medical and tropical health - 1979. (Marseille)

2ND CYCLE

- Master of Cellular and Molecular Biology (Rennes 1986)
- Master of General Human Physiology (Rennes)
- Graduate Certificate in Human Nutrition and Dietetics (Nancy)
- Graduate Certificate in General Immunology (Angers)
- Master of Human Biology (section Physiology) Rennes

1ST CYCLE

- CPEBH Mention Bien (Rennes 1970)

EXPERIENCE PROFESSIONNELLE

• Functions at Rennes University Hospital

2012	Head of the Neurosciences Departement
1997- 2012	Head of the Neurology Service
1990 -2015	Academic Professor and Medical Doctor
October 1984- June 1990	Medical Doctor Internal Medecine
October 1981- September 1984	Clinical Assistant
April 1975 – September 1981	residency

• Mobility

November 2012 – March 2013	Invited Professor (ICM Paris)
April 1996 – September 1996	Visiting Professor (M.S.Clinic - Pr. Paty) VANCOUVER- CANADA
September 1987 – September 1988	Research Fellow Department of Neurology (Pr Hughes) LONDON (UK)
Avril 1977- Juin 1978	Assistant Doctor (Dr LEBOURG) BOUAKE- Ivory Coast

• Scientific Committee

- Member of the Scientific Committee of the Association on MS Research es (ARSEP) 1990-2012
- Member of the Scientific Committee of the Ligue Française contre la sclérose en Plaques (LFSEP) 1994-2012.
- Member of the European Committe for treatment and Research in Multiple Sclerosis (ECTRIMS) 1996-2006
- Member of the Advisory Committee on Clinical Trials of New Drugs for the National Multiple Sclerosis Society (USA) January 2000 / 31 December 2002.

• « Reviewer »

- Revue Neurologique
- Journal of Neurology, Neurosurgery and Psychiatry
- Journal of Multiple Sclerosis
- Journal of Neurology
- Journal of neurological sciences
- Brain
- Lancet neurology
- Lancet
- New England Journal of Medecine

- **International and national positions**

- President of the Société Française de Neurologie 2017-2018
- Vice president of the European Charcot Foundation since 2013
- Fellow of the European Academy of Neurology since 2015

- **Other titles**

- President of the Fond de Dotation INCR www.incr.fr
- President of the Association Neuro-bretagne www.neurobretagne-oniric.com
- Directeur of the Inter-regional Programme West Neurosciences Network of Excellence

GRANTS

Acronymn	National/ international	National PI	Funding :		Promotor
EMISEP	National	EDAN Gilles	Académic (100%)	PHRC National	CHU DE RENNES
IQALY-SEP	National	EDAN Gilles	Académic (100%)	PHRC National	CHU DE RENNES
MITOX-REBIF	International	EDAN Gilles	Grant	industrial	CHU Rennes
MUSIC	National	EDAN Gilles	Academic + Grant	PHRC inter régional	CHU DE RENNES

List of the publications (2014 – 2018)

1) **Edan G.**

Natalizumab in secondary progressive multiple sclerosis.
Lancet Neurol. 2018 Mar 12. pii: S1474-4422(18)30108-X. **IF =28,2**

2) Fernández O, Delvecchio M, **Edan G**, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Vermersch P, Comi G. Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management. Eur J Neurol. 2018 Jan 21. doi: 10.1111/ene.13581 **IF =4**

3) Kalson-Ray S, **Edan G**, Leray E; SURVIMUS Study Group. An excessive risk of suicide may no longer be a reality for multiple sclerosis patients. Mult Scler. 2017 May;23(6):864-871. **IF 4.8**

4) Fernández O, Delvecchio M, **Edan G**, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Vermersch P, Comi G. Survey of diagnostic and treatment practices for multiple sclerosis.Part 1 Eur J Neurol. 2017 Mar;24(3):516-522. **IF: 4.0**

5) Kerbrat A, Combès B, Commowick O, Maarouf A, Bannier E, Ferré JC, Tourbah A, Ranjeva JP, Barillot C, **Edan G**. USPIO-positive MS lesions are associated with greater tissue damage than gadolinium-positive-only lesions during 3-year follow-up. Mult Scler. 2017 Oct 1:1352458517736148. **IF = 4.8**

6) Hammas K, Yaouanq J, Lannes M, **Edan G***, Viel JF*. Small-area distribution of multiple sclerosis incidence in western France: in search of environmental triggers. Int J Health Geogr. 2017 Sep 21;16(1):35.

7) **Edan G**, Kerbrat A. Inhibitor of Fatty Amide Hydrolase-Learning from Tragic Failures. N Engl J Med. 2017 Jan 26;376(4):393-4. **IF: 72.4**

8) **Edan G**. French Society of Neurology award : The excellence in Neurology 2016. Rev Neurol (Paris). 2017 Mar;173 Suppl 2:S33-S34. **IF = 1**

9) Bonenfant J, Bajoux E, Deburghraeve V, Le Page E, **Edan G*** and Kerbrat A*. Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis ? Eur J Neurol. 2017 Feb;24(2):237-244. **IF: 4.0**

10) **Edan G**. Adress from the President, January 2017. Rev Neurol (Paris). 2017 Jan - Feb;173(1-2):4 **IF=1**

- 11) Kerbrat A, Ferré JC, Fillatre P, Ronzière T, Vannier S, Carsin-Nicol B, Lavoué S, Vérin M, Gauvrit JY, Le Tulzo Y, **Edan G**.
Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase
N Engl J Med. 2016 Nov 3;375(18):1717-1725. **IF: 72.4**
- 12) Gonsette R, Debouvier M, Sindic C, Ferré JC, **Edan G**.
Plixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.
Mult Scler. 2016 May;22(6):817-21. **IF 4.8**
- 13) Tourbah A, Lebrun C, **Edan G**, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouvier M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
Mult Scler. 2016 Nov;22(13):1719-1731. **IF 4.8**
- 14) Kappos L, **Edan G**, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
Neurology. 2016 Sep 6;87(10):978-87. **IF: 8.3**
- 15) Leray E, Moreau T, Fromont A, **Edan G**.
Epidemiology of multiple sclerosis.
Rev Neurol (Paris). 2016 Jan;172(1):3-13 **IF=1**
- 16) Barillot C, **Edan G**, Commowick O.
Imaging biomarkers in multiple Sclerosis: From image analysis to population imaging.
Med Image Anal. 2016 Oct;33:134-139. **IF: 3.5**
- 17) Maarouf A, Ferré JC, Zaaoui W, Le Troter A, Bannier E, Berry I, Guye M, Pierot L, Barillot C, Pelletier J, Tourbah A, **Edan G**, Audoin B, Ranjeva JP.
Ultra-small superparamagnetic iron oxide enhancement is associated with higher loss of brain tissue structure in clinically isolated syndrome.
Mult Scler. 2016 Jul;22(8):1032-9. **IF 4.8**
- 18) Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, **Edan G**.
Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
Lancet. 2015 Sep 5;386(9997):974-81. **IF: 47.8**
- 19) Leray E, Vukusic S, Debouvier M, Clanet M, Brochet B, de Sèze J, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, **Edan G**.
Excess Mortality in patients with multiple sclerosis starts at 20 years from clinical onset : Data from a large-scale French observational study.
PLoS One. 2015 Jul 6;10(7):e0132033. **IF: 3.5**
- 20) Le Page E, Deburghgraeve V, Lester MA, Cardiet I, Leray E, **Edan G**.
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
J Neurol. 2015;262(4):1024-34. **IF: 3.4**
- 21) Yaouanq J, Tron I, Kerbrat A, Leray E, Hamonic S, Merienne M, Hinault P, **Edan G**.
Register-based incidence of multiple sclerosis in Brittany (north western France), 2000-2001.
Acta Neurol Scand. 2015 May;131(5):321-8. **IF: 3.0**
- 22) Kerbrat A, Hamonic S, Leray E, Tron I, **Edan G*** and Yaouanq J*;
Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients. West Neuroscience Network of Excellence (WENNE).
Eur J Neurol. 2015 Mar;22(3):507-e35. **IF: 4.0**
- 23) Commowick O, Maarouf A, Ferré JC, Ranjeva JP, **Edan G***, Barillot C*.
Diffusion MRI abnormalities detection with orientation distribution functions: a multiple sclerosis longitudinal study.
Med Image Anal. 2015 May;22(1):114-23. **IF: 3.5**
- 24) Spinal cord hemorrhage in a patient with neurosarcoidosis on long-term corticosteroid therapy : case report.
Pegat B, Drapier S, Morandi X, **Edan G**.
BMC Neurol. 2015 Jul 30;15:123. **IF=2**
- 25) Sindic C, **Edan G**.
Richard E Gonsette (1929-2014)
Mult Scler. 2015 Apr;21(5):540. **IF= 4,8**
- 26) Robert F, **Edan G**, Nicolas G, Pouget J, Vial C, Antoine JC, Puget S.
A retrospective study on the efficacy and safety of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy.
Presse Med. 2015 Jul-Aug;44(7-8) **IF<1**
- 27) Devy R, Lehert P, Varlan E, Genty M, **Edan G**.
Improving the quality of multiple sclerosis patients through coping strategies in routine medical practice.
Neurol Sci. 2015 Jan;36(1):85-90. **IF : 1,7**
- 28) **Edan G**, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D; BENEFIT Study Group
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. .
J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1183-9. **IF: 3.4**

29) Crimi A, Commowick O, Maarouf A, Ferré JC, Bannier E, Tourbah A, Berry I, Ranjeva JP, **Edan G**, Barillot C. Predictive value of imaging markers at multiple sclerosis disease onset based on gadolinium- and USPIO-enhanced MRI and machine learning. PLoS One. 2014 Apr 1;9(4):e93024. **IF: 3.5**

30) **Edan G**, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D; 2013 Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. for the BENEFIT Study Group. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1183-9 **IF 4,6**

Oral presentations during International conferences since 2014

- 2017 : invitationECTRIMS (Paris- October 2017) : Predictive factors of progressive MS
- 2017 : invitation LACTRIMS (Buenos Aires) Clinical prognostic factors in RMS
- 2017 : invitation EAN (Amsterdam) : « teaching course » : When and How to decide an induction strategy
- 2017 : invitation EAN spring school (Prague) : From Epidemiological Data to Therapeutic Strategy
- 2016 : invitation DGN meeting, (Manheim) « From Epidemiological Data to Therapeutic Strategy”
- 2016 : invitation : 24th meeting of the ECF (Milan) “lecture” DMD Treatment Approval for MS : 20 years later !
- 2016 : Invitation :ECTRIMS (London) “The initial treatment of early active relapsing remitting MS should be with a potent induction therapy rather than standard immunomodulation then escalation”
- 2015 : Invitation Symposium Cambridge (UK) : “From Epidemiological Data to Therapeutic Strategy”
- 2015 Invitation au 3rd International Porto Congress Of Multiple Sclerosis : « Natural history of MS »
- 2014 Invitation Neuro-immunology symposium (Bruxelles) “Therapeutic Strategy in MS : Past-Present-Future”
- 2014 Invitation à ENS/EFNS (Istanbul):”Teaching course: Induction Therapy for Patients with Multiple Sclerosis: WHY?, WHEN?, HOW?”

Rennes, April 15th, 2019

